Skip to main content

Market Overview

AstraZeneca's Imfinzi, Tremelimumab Combo Boosts Overall Survival In Lung Cancer

Share:
AstraZeneca's Imfinzi, Tremelimumab Combo Boosts Overall Survival In Lung Cancer
  • A combination of AstraZeneca Plc's (NASDAQ: AZN) Imfinzi (durvalumab), tremelimumab, and chemotherapy has extended overall survival (OS) when used as a first-line treatment for stage IV (metastatic) non-small cell lung cancer (NSCLC).
  • A final analysis of data from the POSEIDON Phase 3 study shows that the combination demonstrated a statistically significant and clinically meaningful OS benefit versus chemotherapy alone.
  • The trial also tested a combination of Imfinzi plus chemotherapy, which, while showing a statistically significant improvement in progression-free survival (PFS) versus chemotherapy, failed to improve OS significantly.
  • Each combination demonstrated an acceptable safety profile, and no new safety signals were identified.
  • The data will be presented at a forthcoming medical meeting.
  • Price Action: AZN shares are up 0.62% at $53.81 during the market trading session on the last check Friday.
 

Related Articles (AZN)

View Comments and Join the Discussion!

Posted-In: Briefs Non-Small Cell Lung Cancer Phase 3 TrialBiotech News Health Care General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com